ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BAX / forecast
PEN (57) GMED (69) PODD (72) SOLV (44) ⌘ Pro Terminal →

Baxter International Inc. (BAX) 12-Month Stock Forecast & Price Target Cone

$24.22 +5.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.41

Baxter International Inc. (BAX) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $11.90B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Baxter International Inc. (NYSE: BAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $24.22 (+5.30% 1D, market cap $11.90B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, BAX ranks #257 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BAX compare to PEN and GMED in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BAX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 30.1%, and ROIC of -2.4%. By comparison, PEN (Penumbra Inc.) holds a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.57B) and GMED (Globus Medical Inc.) posts a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BAX?
▼

Per BAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000010456), Baxter International Inc. generated $11.24B in revenue (+5.7% YoY), -$957.0M in net income, and $339.0M in free cash flow against $20.05B in total assets and $6.28B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $24.40 (+0.76%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510050
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Cash (10)Whales (9)SEC (10)Macro (9)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
$32 Bull$23 Base$18 Bear
📬 FREE BAX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BAX)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY BAX SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 3% FCF Margin ($339.0M FCF) & 30.1% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (39) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
58
Grade C$24.80-0.4% Next Q
Q2 (-2Q)
55
Grade C$24.70+3.1% Next Q
Q3 (-1Q)
53
Grade C-$25.46-4.9% Next Q
Current
50
Grade D$24.22-1.4% Hist 90D α
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BAX currently carries a cautious 50/100 (D) rating due to Macro Regime Fit (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.40) and Max Pain ($25.43) forces dealer call-delta covering toward $31.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 50%NO 50%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BAX Position Size: $10,000

Shares at $24.22: 412.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $18.21
$7,519
$-2,481 (-24.8%)
12M Consensus BaseTarget $23.35
$9,641
$-359 (-3.6%)
12M Bull Case BreakoutTarget $31.50
$13,006
+$3,006 (+30.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$2474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$3069%B
JP MorganUS Large-Cap ResearchSELL$2158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BAX)

  • ✓Walkthrough of BAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.73%📐 WEDGE COMPRESSION COIL
2026-11-03O $23.50H $24.22L $23.00C $24.22VOL 11.82M
RES: $25.86SUP: $22.55SMA50: $24.40SMA200: $21.39
$30.95$27.03$23.10$19.18$15.26RES $25.86SUP $22.55$24.222026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BAX Butterfly Map → + Track BAX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
11.2%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BAX)

Health Care Rank #257 of 1015 ⚔️ PEN vs BAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BAX vs. PEN, GMED, PODD, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Baxter International Inc. (BAX) ranks #257 by composite RQD confidence (50/100, grade D) and #91 by equity capitalization ($11.90B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with BAX at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BAX ACTIVE
Baxter International Inc.
D 50/100 — 30.1% -2.4% +5.30% $11.90B Benchmark Subject
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% +0.75% $12.57B /pen-vs-bax →
GMED
Globus Medical Inc.
C+ 69/100 20.7x 67.4% 8.7% +1.81% $10.48B /gmed-vs-bax →
PODD
Insulet Corporation
B 72/100 42.8x 71.6% 20.4% +2.63% $10.38B /podd-vs-bax →
SOLV
Solventum Corporation
D 44/100 9.1x 53.5% 18.7% +4.21% $13.84B /solv-vs-bax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000010456 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Baxter International Inc. (BAX) reported GAAP revenue of $11.24B (+5.7% vs. FY2024 revenue of $10.64B , and +8.5% cumulative change since FY2023) , GAAP net income of -$957.0M, operating cash flow of $845.0M, and free cash flow of $339.0M (-37.3% YoY). On the balance sheet, BAX closed FY2025 with $20.05B in total assets against $6.28B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $11.24B -$957.0M $845.0M $339.0M $20.05B $6.28B
FY2024 (FY) 2024-12-31 $10.64B -$649.0M $1.02B $540.4M $25.78B $8.44B
FY2023 (FY) 2023-12-31 $10.36B $2.66B $1.73B $1.26B $12.43B $2.91B

3. BAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Baxter International Inc. (NYSE: BAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $24.22 (+5.30% 1D, market cap $11.90B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, BAX ranks #257 in composite RQD confidence.

How does BAX compare to PEN and GMED in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BAX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 30.1%, and ROIC of -2.4%. By comparison, PEN (Penumbra Inc.) holds a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.57B) and GMED (Globus Medical Inc.) posts a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BAX?

Per BAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000010456), Baxter International Inc. generated $11.24B in revenue (+5.7% YoY), -$957.0M in net income, and $339.0M in free cash flow against $20.05B in total assets and $6.28B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BAX trading relative to its 50-day, 200-day, and 52-week technical levels?

BAX last traded at $24.22 (+5.30% on volume of 10,163,354 shares), positioning the stock -0.74% below its 50-day simple moving average ($24.40) and +13.23% above its 200-day simple moving average ($21.39). Across its 52-week range of $15.73 to $30.00, BAX sits at the 59.5% percentile with a 14-day RSI of 39.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.4% ($22.19 to $26.25).

Direct Sub-Reports: BAX RQD Cockpit BAX 12M Forecast BAX Earnings & Move BAX Dividends & DRIP BAX Insiders & 13F BAX Whale Options BAX Profit Sankey BAX News & Why
ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ SEC XBRL & RQD VERIFIED

BAX — Baxter International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Baxter International Inc. (BAX) earns a live Roarable RQD composite score of 50/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $24.22 (+5.30% 1D, market capitalization $11.90B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -2.4%, gross margin of 30.1%, operating margin of -2.7%, and free cash flow yield of 2.79%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 0.95x equity beta, Altman Z-Score of 2.22, Piotroski F-Score of 6/9, and Debt/Equity of 0.96x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Baxter International Inc. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. The profile identifies the company as a Health Care issuer but does not describe its products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Baxter International Inc. (BAX) reported $11.24B in annual revenue (up from $10.64B in FY2024, +5.7% YoY) and -$957.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($10.36B revenue, $2.66B net income) through FY2025, BAX scaled operating cash flow to $845.0M and free cash flow to $339.0M, backed by $20.05B in total assets against $6.28B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 50/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 2.79% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $15.73 – $30.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against -2.7% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context is the Health Care / Medical/Dental Instruments classification.

  • Key Question #1: Can BAX sustain or expand its -2.7% operating margin and -2.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $11.24B and free cash flow of $339.0M, how will capital allocation balance growth reinvestment against $6.28B in total debt?
  • Key Question #3: How sensitive is BAX's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

BAX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Baxter International Inc. (BAX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BAX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BAX Bull vs. Bear Conversation Board — What's Your Call at $24.22?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BAX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BAX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $28.06 (+22.0%)
📌 Pinned Debate

A 2.79% FCF yield and an 18x forward P/E offer a cash-flow valuation case if earnings recover from trailing losses.

Picked up a starter position in BAX in my $100K Virtual Cash book at $23.00. A 2.79% FCF yield and an 18x forward P/E offer a cash-flow valuation case if earnings recover from trailing losses.. Trading inside a $15.73–$30.00 52-week range with 2.79% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@SkepticalCFA Fair point on 18.0x forward P/E, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (30.1%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $19.78 (-14.0%)
Spot @ $23.00

Negative ROIC of -2.4%, an operating loss of -$308.0M in FY 2025, and a rating flagged as a distribution warning point to deteriorating

Negative ROIC of -2.4%, an operating loss of -$308.0M in FY 2025, and a rating flagged as a distribution warning point to deteriorating economics.. Look at the math on BAX: paying 18.0x forward P/E for -2.4% ROIC and -2.7% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $20.24 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%